Potent and selective p38 MAP kinase inhibitor (IC50
= 44 nM for p38α
). Displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580
(Cat. Nos. 1202 and 1402). Reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
Barone et al.
The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury.
Legos et al.
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 239063 include:
Showing Results 1 - 4 of 4